A Message From the Chair

Rogerio C. Lilenbaum, MD

The field of lung cancer has undergone another revolution. Following the advent of immunotherapy and checkpoint inhibitors, following the continued expansion of targeted therapies to include ALK, EGFR, ROS1, BRAF, and NTRK, the latest revolution in lung cancer is the combination of the Winter Lung and Miami Lung Cancer Conferences.

This year will be a year of firsts, even as we enter our 16th year at Winter Lung. I am so excited to be joined again by Mark A. Socinski, MD, of the Florida Hospital Cancer Institute and to team up with Heather A. Wakelee, MD, from Stanford University Medical Center, and Julie R. Brahmer, MD, from Sidney Kimmel Cancer Center at Johns Hopkins who have steadfastly led Miami Lung.

Patients with cancer have the best outcomes when doctors collaborate. The benefits of a multidisciplinary team consisting of medical oncologists, surgeons, radiologists, pathologists, PAs, NPs, and nurses is obvious. This year, we take extend that philosophy to CME.

The collaboration of Winter Lung and Miami Lung, through the help of Physicians’ Education Resource® LLC (PER®) will be the most cutting-edge and practice-focused CME meeting in lung cancer. The established format of Winter Lung’s fast didactic lectures in combination with Miami Lung’s dynamic Medical Crossfire® debates is going to create a truly unique meeting.

I can’t wait for this year’s meeting in Miami, to collaborate further, and for you to join us!

Sincerely,

Rogerio C. Lilenbaum, MD
Professor of Medicine in Medical Oncology
Chief Medical Officer of Smilow Cancer Hospital
Yale New Haven Health
New Haven, CT
A COMBINED MEETING

The Winter Lung Cancer Conference™ has been an escape to Miami every February for the past 16 years. During those long winter months, dedicated physicians, oncologists, and health care professionals flocked to Miami for an engaging weekend of CME, the latest date, and updates to practices.

The name Winter Lung has become synonymous with expertise, speed, and precision. At Winter Lung, the clock is always ticking and each lecture is honed to its finest points. What ALK inhibitor should you choose following progression? Which patients should start on a checkpoint inhibitor? What was the key takeaway from the latest trial? All questions answered in 15 minutes or less!

Across town, the Miami Lung Cancer Conference® was also advancing lung cancer CME. One of three Miami-based oncology meetings hosted by PER®, Miami Lung is famous for its Medical Crossfire® formats. More than a discussion and more than a debate, a Medical Crossfire® is a meeting of experts focused on answering the field’s toughest questions.

This year, Miami Lung and Winter Lung have become one, conserving the best parts of both meetings. Join us this year, this time in January, for the fast pace of Winter Lung and Crossfires of Miami Lung.

TWO WAYS TO REGISTER

Online

gotoper.com /go/WLC19TRI

Phone

609-378-3701
A PREVIEW OF THIS YEAR’S TOPICS

Friday, January 25, 2019
• Welcome and Keynote Address

Saturday, January 26, 2019
• EGFR and ALK in the first-, second-, and third-line
• Overcoming mechanisms of resistance for targeted therapy
• New oncogenic drivers including ROS1 and BRAF
• Future targets, such as RET, MET, and HER2
• Practical applications of immunotherapy
• I/O as a single-agent or in combination
• Differences in approaching squamous and nonsquamous NSCLC
• Fighting immunotherapy resistance pathways
• Current topics in lung cancer surgery
• Best practices for radiation therapy in lung cancer
• I/O and targeted therapies in the neoadjuvant setting

Sunday, January 27, 2019
• Methods to integrate palliative care
• The future of lung cancer therapy
• Immunotherapy beyond PD-(L)1 and CTLA-4
• What are the new standards for small cell lung cancer?
• Emerging approaches for mesothelioma
• Role of I/O for unresectable disease
• Managing immune-related adverse events
• Determining biomarkers for checkpoint inhibitors: PD-L1 vs. TMB
• What are the new standards of care?

Program Co-Chairs
Rogerio C. Lilenbaum, MD
Professor of Medicine in Medical Oncology
Chief Medical Officer of Smilow Cancer Hospital – Yale New Haven Health
New Haven, CT

Mark A. Socinski, MD
Executive Medical Director
Florida Hospital Cancer Institute
Orlando, FL

Julie Brahmer, MD
Interim Director
Associate Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Heather A. Wakelee, MD
Professor, Medicine (Oncology)
Stanford University Medical Center
Stanford, CA

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for a maximum of 11.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 11.0 Contact Hours.
This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, and Celgene Corporation.
Save the Date!

16th Annual Winter Lung Cancer Conference

Combined with the Miami Lung Cancer Conference

JANUARY 25-27, 2019 • MIAMI, FL

• Network with Expert Faculty and Your Colleagues
• Integrate Recent Data into Your Practice Tomorrow!

For more information visit us online now at…

gotoper.com/go/WLCC18NEWS

Program Co-Chairs

Rogerio C. Lilenbaum, MD
Professor of Medicine in Medical Oncology
Chief Medical Officer of Smilow Cancer Hospital –
Yale New Haven Health
New Haven, CT

Mark A. Socinski, MD
Executive Medical Director
Florida Hospital Cancer Institute
Orlando, FL

Heather A. Wakelee, MD
Professor, Medicine (Oncology)
Stanford University Medical Center
Stanford, CA

Julie Brahmer, MD
Interim Director
Associate Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

“ A GREAT MEETING WITH GREAT SPEAKERS AND GREAT DISCUSSION.”